1. Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949. (15th November 2016) Authors: Stalder, Anna K.; Lott, Dominik; Strasser, Daniel S.; Cruz, Hans G.; Krause, Andreas; Groenen, Peter M.A.; Dingemanse, Jasper Journal: British journal of clinical pharmacology Issue: Volume 83:Number 3(2017:Mar.) Page Start: 476 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Estimation of Attainment of Steady‐State Conditions for Compounds With a Long Half‐Life. (12th July 2020) Authors: Krause, Andreas; Lott, Dominik; Dingemanse, Jasper Journal: Journal of clinical pharmacology Issue: Volume 61:Number 1(2021) Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model. Issue 1 (6th June 2022) Authors: Aldea, Roxana; Grimm, Hans Peter; Gieschke, Ronald; Hofmann, Carsten; Lott, Dominik; Bullain, Szofia; Delmar, Paul; Klein, Gregory; Lyons, Marco; Piazza, Fabrizio; Carare, Roxana O.; Mazer, Norman A. Journal: Alzheimer's & dementia Issue: Volume 8:Issue 1(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Linking amyloid to clinical outcome: A quantitative semi‐mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer's disease and the effects of anti‐amyloid treatment. (20th December 2022) Authors: Mazer, Norman A; Hofmann, Carsten; Lott, Dominik; Gieschke, Ronald; Klein, Gregory; Boess, Frank; Grimm, Hans Peter; Kerchner, Geoffrey A.; Baudler, Monika; Smith, Janice; Schobel, Scott; Doody, Rachelle S. Journal: Alzheimer's & dementia Issue: Volume 18(2022)Supplement 3 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P1 Receptor Modulator Ponesimod. Issue 6 (27th October 2017) Authors: Lott, Dominik; Lehr, Thorsten; Dingemanse, Jasper; Krause, Andreas Journal: Clinical pharmacology & therapeutics Issue: Volume 103:Issue 6(2018) Page Start: 1083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Modelling pharmacokinetics and pharmacodynamics of the selective S1P1 receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients. Issue 4 (14th January 2020) Authors: Lott, Dominik; Juif, Pierre‐Eric; Dingemanse, Jasper; Krause, Andreas Journal: British journal of clinical pharmacology Issue: Volume 86:Issue 4(2020) Page Start: 791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT‐774312: A novel CRTH2 antagonist. Issue 6 (11th February 2019) Authors: Géhin, Martine; Lott, Dominik; Farine, Hervé; Issac, Milena; Strasser, Daniel; Sidharta, Patricia; Dingemanse, Jasper Journal: Basic & clinical pharmacology & toxicology Issue: Volume 124:Issue 6(2019) Page Start: 711 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist. (16th November 2022) Authors: Krause, Andreas; Lott, Dominik; Brussee, Janneke M.; Muehlan, Clemens; Dingemanse, Jasper Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 12:Number 1(2023) Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗